Travere Therapeutics just saw its modeled fair value per share move slightly, from US$42.36 to US$42.50, in the latest analyst update. That modest shift sits against a backdrop of Street research ...

This week, the FDA flexed its regulatory authority to approve the first medicine to treat focal segmental glomerulosclerosis, ...

The latest health news includes calls for transparency in FDA's accelerated drug approvals, expanded use of Travere's kidney drug, Roche's new study for gene therapy, and Hetero's global drug rollout ...

The FDA is revisiting its stance on compounded peptides with plans for advisory panel meetings. Also, a sweeping Cochrane ...

Abbott stock took a hit early Thursday on lackluster guidance for the year and second quarter following the takeover of Exact ...